149 related articles for article (PubMed ID: 15304031)
1. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia.
Bonomini M; Dottori S; Amoroso L; Arduini A; Sirolli V
J Thromb Haemost; 2004 Aug; 2(8):1275-81. PubMed ID: 15304031
[TBL] [Abstract][Full Text] [Related]
2. L-carnitine inhibits a subset of platelet activation responses in chronic uraemia.
Bonomini M; Sirolli V; Dottori S; Amoroso L; Di Liberato L; Arduini A
Nephrol Dial Transplant; 2007 Sep; 22(9):2623-9. PubMed ID: 17478491
[TBL] [Abstract][Full Text] [Related]
3. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia.
Elshamaa MF; Elghoroury EA; Helmy A
Blood Coagul Fibrinolysis; 2009 Jun; 20(4):230-9. PubMed ID: 19521197
[TBL] [Abstract][Full Text] [Related]
4. Calpain inhibition by calpeptin does not prevent APLT activity reduction in PS-exposing platelets, but calpeptin has independent pro-apoptotic effects.
Gwozdz AM; Leung R; Wang H; Bang KW; Packham MA; Freedman J; Rand ML
Thromb Haemost; 2010 Jun; 103(6):1218-27. PubMed ID: 20352156
[TBL] [Abstract][Full Text] [Related]
5. Persistence of procoagulant surface expression on activated human platelets: involvement of apoptosis and aminophospholipid translocase activity.
Leung R; Gwozdz AM; Wang H; Bang KW; Packham MA; Freedman J; Rand ML
J Thromb Haemost; 2007 Mar; 5(3):560-70. PubMed ID: 17155950
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation.
Presseizen K; Friedman Z; Shapiro H; Radnay J; Ellis MH
Clin Appl Thromb Hemost; 2002 Jan; 8(1):33-9. PubMed ID: 11991237
[TBL] [Abstract][Full Text] [Related]
7. Enhanced platelet apoptosis in chronic uremic patients.
Li M; Wang Z; Ma T; Lu G; Yan R; Zhao L; Deng K; Dai K
Ren Fail; 2014 Jul; 36(6):847-53. PubMed ID: 24655051
[TBL] [Abstract][Full Text] [Related]
8. Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation.
van Kruchten R; Mattheij NJ; Saunders C; Feijge MA; Swieringa F; Wolfs JL; Collins PW; Heemskerk JW; Bevers EM
Blood; 2013 Mar; 121(10):1850-7. PubMed ID: 23303820
[TBL] [Abstract][Full Text] [Related]
9. Merocyanine 540 as a fluorescent probe of altered membrane phospholipid asymmetry in activated whole blood platelets.
Watala C; Waczulikova I; Wieclawska B; Rozalski M; Gresner P; Gwoździński K; Mateasik A; Sikurova L
Cytometry; 2002 Nov; 49(3):119-33. PubMed ID: 12442312
[TBL] [Abstract][Full Text] [Related]
10. Maintaining flippase activity in procoagulant platelets is a novel approach to reducing thrombin generation.
Millington-Burgess SL; Harper MT
J Thromb Haemost; 2022 Apr; 20(4):989-995. PubMed ID: 35034417
[TBL] [Abstract][Full Text] [Related]
11. Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction.
Wolfs JL; Comfurius P; Rasmussen JT; Keuren JF; Lindhout T; Zwaal RF; Bevers EM
Cell Mol Life Sci; 2005 Jul; 62(13):1514-25. PubMed ID: 15971000
[TBL] [Abstract][Full Text] [Related]
12. Vitamin E inhibition on platelet procoagulant activity: involvement of aminophospholipid translocase activity.
Kim JE; Han M; Hanl KS; Kim HK
Thromb Res; 2011 May; 127(5):435-42. PubMed ID: 21296386
[TBL] [Abstract][Full Text] [Related]
13. Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome.
Gao C; Xie R; Yu C; Wang Q; Shi F; Yao C; Xie R; Zhou J; Gilbert GE; Shi J
Thromb Haemost; 2012 Apr; 107(4):681-9. PubMed ID: 22370875
[TBL] [Abstract][Full Text] [Related]
14. Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation.
Rand ML; Wang H; Pluthero FG; Stafford AR; Ni R; Vaezzadeh N; Allison AC; Kahr WH; Weitz JI; Gross PL
J Thromb Haemost; 2012 Jun; 10(6):1109-19. PubMed ID: 22463102
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylserine surface expression and integrin alpha IIb beta 3 activity on thrombin/convulxin stimulated platelets/particles of different sizes.
Rukoyatkina N; Begonja AJ; Geiger J; Eigenthaler M; Walter U; Gambaryan S
Br J Haematol; 2009 Feb; 144(4):591-602. PubMed ID: 19036116
[TBL] [Abstract][Full Text] [Related]
16. PKC inhibition markedly enhances Ca2+ signaling and phosphatidylserine exposure downstream of protease-activated receptor-1 but not protease-activated receptor-4 in human platelets.
Harper MT; Poole AW
J Thromb Haemost; 2011 Aug; 9(8):1599-607. PubMed ID: 21649850
[TBL] [Abstract][Full Text] [Related]
17. Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle Release.
Gao C; Xie R; Yu C; Ma R; Dong W; Meng H; Zhang Y; Si Y; Zhang Z; Novakovic V; Zhang Y; Kou J; Bi Y; Li B; Xie R; Gilbert GE; Zhou J; Shi J
PLoS One; 2015; 10(11):e0142835. PubMed ID: 26580207
[TBL] [Abstract][Full Text] [Related]
18. Hemodialysis, erythropoietin and megakaryocytopoiesis: factors in uremic thrombocytopathy and thrombophilia.
Zwaginga JJ
J Thromb Haemost; 2004 Aug; 2(8):1272-4. PubMed ID: 15304030
[No Abstract] [Full Text] [Related]
19. Glycoprotein IIb/IIIa blockade inhibits platelet aminophospholipid exposure by potentiating translocase and attenuating scramblase activity.
Razmara M; Hu H; Masquelier M; Li N
Cell Mol Life Sci; 2007 Apr; 64(7-8):999-1008. PubMed ID: 17372676
[TBL] [Abstract][Full Text] [Related]
20. Formaldehyde-fixation of platelets for flow cytometric measurement of phosphatidylserine exposure is feasible.
Rochat S; Alberio L
Cytometry A; 2015 Jan; 87(1):32-6. PubMed ID: 25266200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
